
SciBase Secures $600,000 Order to Expand Castle Biosciences Partnership
A fresh $600,000 order for Nevisense Go devices and electrodes signals a deepening partnership between Stockholm-based SciBase and U.S. diagnostics firm Castle Biosciences. The deal funds an accelerated timeline for their ongoing atopic dermatitis study while laying the groundwork for a second clinical trial starting in late 2026.



























